Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2021

Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A Common Stock is as follows (in thousands, except share and per share amounts):

	For the Three Months Ended March 31,
	2021			2020
Numerator:
Net loss	$	(5,942	)	$	(7,165	)
Less: Net loss attributable to noncontrolling interests		(1,701	)		(2,441	)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted		(4,241	)		(4,724	)
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted		56,472,535			43,462,551
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.08	)	$	(0.11	)

Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:

	March 31, 2021		March 31, 2020
Class B Common Stock ⁽¹⁾		23,093,860		23,094,221
Common stock options granted under the Plan		4,404,403		2,531,143
Common stock options granted under Letter Agreements		—		2,500,000
Common stock warrants		2,014,503		2,014,503
Total		29,512,766		30,139,867

(1)

Shares of Class B Common Stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B Common Stock under the two-class method has not been provided. Each share of Class B Common Stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A Common Stock.